Methergin

Methylergometrine, the active ingredient in Methergin, is an ergot alkaloid presented as a sterile injectable solution for intramuscular, intravenous, or subcutaneous use. It is indicated for the prevention and treatment of postpartum hemorrhage and uterine atony in obstetric patients, promoting uterine contraction during the immediate postpartum period to reduce bleeding.

GNH USA supplies Methergin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics, and procurement teams worldwide, ensuring quality‑controlled shipments and regulatory compliance. The company adheres to Good Distribution Practice and provides support for customs clearance and cold‑chain logistics where required.

Methylergometrine is a uterotonic agent used in obstetric care to manage uterine muscle tone.

Postpartum hemorrhage: reduces bleeding by stimulating strong uterine contractions after delivery. Uterine atony: restores tone in a relaxed uterus to prevent excessive blood loss. Obstetric hemorrhage prophylaxis: administered prophylactically to lower the risk of postpartum bleeding.

Methylergometrine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Abdominal pain - Headache - Dizziness - Hypertension

Serious or Rare Side Effects: - Coronary artery spasm - Severe hypertension - Pulmonary edema - Uterine rupture - Allergic reactions (including anaphylaxis) - Gangrene of extremities

Use of Methergin requires careful consideration of patient history and clinical conditions.

Pregnancy: contraindicated (Category X) because it may cause uterine hyperstimulation and fetal harm. Breastfeeding: not recommended as the drug can be excreted in milk. Cardiovascular disease: avoid in patients with uncontrolled hypertension, coronary artery disease, or peripheral vascular disease. Severe hepatic or renal impairment: use with caution and monitor plasma levels. Drug interactions: avoid concomitant use with other vasoconstrictive agents or MAO inhibitors. Store below 25°C: keep in the original container, protect from light and moisture.

Methylergometrine can interact with several medicines, affecting its safety and efficacy.

Major Interactions (Avoid): - Monoamine oxidase (MAO) inhibitors - Ergotamine or other ergot derivatives - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) - Other vasoconstrictive agents

Moderate Interactions (Monitor Closely): - Antihypertensive drugs such as beta‑blockers or calcium channel blockers - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents - Diuretics that may alter electrolyte balance - Drugs affecting hepatic metabolism that could modify plasma concentrations